MX2023004113A - Metodo para el tratamiento de enfermedades relacionadas con ox40. - Google Patents

Metodo para el tratamiento de enfermedades relacionadas con ox40.

Info

Publication number
MX2023004113A
MX2023004113A MX2023004113A MX2023004113A MX2023004113A MX 2023004113 A MX2023004113 A MX 2023004113A MX 2023004113 A MX2023004113 A MX 2023004113A MX 2023004113 A MX2023004113 A MX 2023004113A MX 2023004113 A MX2023004113 A MX 2023004113A
Authority
MX
Mexico
Prior art keywords
treating
related disease
antibody
present disclosure
atopic dermatitis
Prior art date
Application number
MX2023004113A
Other languages
English (en)
Spanish (es)
Inventor
Yoshinori Nagata
Mitsuo Sato
Kenji Ootaki
Nobuyuki Imai
Munetake SHIMABE
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Publication of MX2023004113A publication Critical patent/MX2023004113A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023004113A 2020-10-09 2021-10-08 Metodo para el tratamiento de enfermedades relacionadas con ox40. MX2023004113A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063089809P 2020-10-09 2020-10-09
US202063116365P 2020-11-20 2020-11-20
US202163233592P 2021-08-16 2021-08-16
PCT/JP2021/037481 WO2022075476A1 (en) 2020-10-09 2021-10-08 Method for treating ox40 related disease

Publications (1)

Publication Number Publication Date
MX2023004113A true MX2023004113A (es) 2023-06-29

Family

ID=81126528

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004113A MX2023004113A (es) 2020-10-09 2021-10-08 Metodo para el tratamiento de enfermedades relacionadas con ox40.

Country Status (11)

Country Link
US (1) US20230383001A1 (https=)
EP (1) EP4225371A4 (https=)
JP (1) JP2023545084A (https=)
KR (1) KR20230084166A (https=)
CN (1) CN116437955A (https=)
AU (1) AU2021358274A1 (https=)
CA (1) CA3198414A1 (https=)
IL (1) IL301935A (https=)
MX (1) MX2023004113A (https=)
TW (1) TW202222343A (https=)
WO (1) WO2022075476A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL326123A (en) * 2023-07-25 2026-03-01 Inmagene Pte Ltd Treatment methods for alopecia areata and atopic dermatitis
WO2025244002A1 (ja) * 2024-05-21 2025-11-27 国立大学法人京都大学 ベンダムスチンによるｔ細胞の減少を抑制するために使用されるｔ細胞減少抑制剤
WO2025259719A1 (en) * 2024-06-10 2025-12-18 Walden Biosciences, Inc. Method of administering an anti-soluble urokinase plasominogen activator receptor antibody for the treatment of kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2017134292A1 (en) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
PT3528838T (pt) * 2016-09-23 2023-09-04 Hoffmann La Roche Utilizações de antagonistas de il-13 para tratamento de dermatite atópica
WO2019229155A1 (en) * 2018-05-31 2019-12-05 Glenmark Pharmceuticals S.A. Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders

Also Published As

Publication number Publication date
AU2021358274A9 (en) 2024-05-30
TW202222343A (zh) 2022-06-16
IL301935A (en) 2023-06-01
EP4225371A1 (en) 2023-08-16
AU2021358274A1 (en) 2023-05-25
JP2023545084A (ja) 2023-10-26
KR20230084166A (ko) 2023-06-12
CN116437955A (zh) 2023-07-14
WO2022075476A1 (en) 2022-04-14
EP4225371A4 (en) 2024-11-20
CA3198414A1 (en) 2022-04-14
US20230383001A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
PH12021550023A1 (en) Humanized anti-tau antibodies
MX2022001607A (es) Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola.
MX2023004113A (es) Metodo para el tratamiento de enfermedades relacionadas con ox40.
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
PH12019500177A1 (en) Treatment and prevention of sleep disorders
ZA202005388B (en) Methods of treating ulcerative colitis
MX2018002067A (es) Manejo con tetraciclina de dermatosis asociada con inhibidor de egfr.
NI201200171A (es) Anticuerpos hacia gdf8 humano
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
TN2016000142A1 (en) Specific anti-cd38 antibodies for treating human cancers.
AR101740A1 (es) Terapia de combinación y composiciones
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
BR112018071467A2 (pt) método de tratamento ou prevenção de patologias hepáticas
MX2024001954A (es) Anticuerpos il-13 para el tratamiento de la dermatitis atopica.
WO2016127059A3 (en) Light inhibitors for scleroderma and skin fibrotic disease treatment
HK1252514A1 (zh) 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂
PH12016500677A1 (en) Specific anti-cd38 antibodies for treating human cancers
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
MX2022013557A (es) Tratamiento combinado con anticuerpo anti-cd40 contra el cáncer.
BR112019008241A2 (pt) tratamento do prurigo nodular
EA201590884A1 (ru) Способы лечения заболеваний печени
MX2023003723A (es) Anticuerpos anti-il-36r para el tratamiento de dolor inflamatorio cronico.
MY207627A (en) Methods of treating psoriasis